Table 1

Clinical parameters

Indication 1:
variceal bleeding
Indication 2:
refractory ascites
TIPSSStandard careSourceTIPSSStandard careSource
Survival at 12 months0.8600.610100.928*0.553*11
Survival at 24 months0.8600.610100.890*0.241*11
TIPSS technical success0.980N/A190.980N/A19
Shunt dysfunction0.070N/A400.030N/A11
Variceal bleeding at 12 months0.0300.500100.044†0.18221; 11
Variceal bleeding at 24 months0.0300.50010Assume same rates as 12 months
Ascites at 12 months0.1300.330100.5101.00041
HE at 12 months0.2800.400100.3450.33311
% HE severe‡0.2500.250KOLs0.4000.63611
SBP at 12 monthsN/AN/AN/AN/A0.06011
Catheter failure at 12 monthsN/AN/AN/AN/A0.038§20
  • *Survival rates for indication 2 were obtained by estimating parametric survival curves with a lognormal survival function, using 12-month patient data reported in Bureau et al. For further details, see online supplemental appendix 2).

  • †Conservative assumption applied as per economic evaluation of TIPSS for RA by Shen et al.21 The rate of variceal bleeding from Bureau et al is equal to 0% for TIPSS and 18.2% for standard care.11

  • ‡Absolute % of severe HE calculated as overall HE rate multiplied by % HE severe. The remaining HE episodes are classified as mild. % of severe HE obtained from: KOL assumption for variceal bleeding; Bureau et al11 as number of OHE episodes grade >2/total number of OHE episodes.

  • §% with catheter failure at 12 months obtained by extrapolating value from source at 41 weeks (3%), assuming proportional rates between weeks 41 and 52.

  • HE, hepatic encephalopathy; KOL, key opinion leader; N/A, not applicable; RA, refractory ascites; SBP, spontaneous bacterial peritonitis; TIPSS, transjugular intrahepatic stent shunt.